Vaxcyte, Inc. (PCVX)
$67.55+1.12%Close
BUYRECOVERY · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9.8B
- Beta
- 1.23
- P/E (TTM)
- -8.84
- Short % float
- 13.08%
- Days to cover
- 11.4
- SI change
- +7.2%
- 1W
- +0.88%
- 1M
- +14.09%
- vs SPY 1W
- +1.02%
- vs SPY 1M
- +11.58%
Industry peers
FMP comparable companies · ranked by market cap
- PFEBUYPfizer Inc.$158.6BBULLQ 13$27.82+2.96%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.54+3.46%
- MRNABUYModerna, Inc.$78.2BRECOVERYQ 36$197.00+4.65%
- IBRXBUYImmunityBio, Inc.$10.4BRECOVERYQ 8$9.91+1.12%
- VIRBUYVir Biotechnology, Inc.$1.9BRECOVERYQ 12$11.12-1.89%
- NVAXBUYNovavax, Inc.$1.8BBULLQ 10$11.01-1.40%
- VALNSELLValneva SE$540MCRISISQ -1$5.69+1.80%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on PCVX?
- LOPJLB’s latest quantitative signal on Vaxcyte, Inc. (PCVX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is PCVX in?
- Vaxcyte, Inc. (PCVX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Vaxcyte, Inc. (PCVX) do?
- Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasiv…